Interactions between timing and transmissibility explain diverse flavivirus dynamics in Fiji.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
15 03 2021
Historique:
received: 08 06 2020
accepted: 10 02 2021
entrez: 16 3 2021
pubmed: 17 3 2021
medline: 1 4 2021
Statut: epublish

Résumé

Zika virus (ZIKV) has caused large, brief outbreaks in isolated populations, however ZIKV can also persist at low levels over multiple years. The reasons for these diverse transmission dynamics remain poorly understood. In Fiji, which has experienced multiple large single-season dengue epidemics, there was evidence of multi-year transmission of ZIKV between 2013 and 2017. To identify factors that could explain these differences in dynamics between closely related mosquito-borne flaviviruses, we jointly fit a transmission dynamic model to surveillance, serological and molecular data. We estimate that the observed dynamics of ZIKV were the result of two key factors: strong seasonal effects, which created an ecologically optimal time of year for outbreaks; and introduction of ZIKV after this optimal time, which allowed ZIKV transmission to persist over multiple seasons. The ability to jointly fit to multiple data sources could help identify a similar range of possible outbreak dynamics in other settings.

Identifiants

pubmed: 33723237
doi: 10.1038/s41467-021-21788-y
pii: 10.1038/s41467-021-21788-y
pmc: PMC7961049
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1671

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N013638/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206250/Z/17/Z
Pays : United Kingdom

Références

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9294-9299
pubmed: 30150394
Lancet Infect Dis. 2017 Aug;17(8):813-821
pubmed: 28527892
Am J Epidemiol. 2019 Jan 1;188(1):206-213
pubmed: 30165474
PLoS Negl Trop Dis. 2016 Jan 28;10(1):e0004405
pubmed: 26820752
PLoS One. 2018 Jun 7;13(6):e0198487
pubmed: 29879179
Cell. 2019 Aug 22;178(5):1057-1071.e11
pubmed: 31442400
Mol Biol Evol. 2012 Aug;29(8):1969-73
pubmed: 22367748
Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7852-7
pubmed: 27354515
Emerg Infect Dis. 2019 Aug;25(8):1535-1538
pubmed: 31310218
Virus Genes. 2020 Oct;56(5):632-637
pubmed: 32542479
PLoS Med. 2019 Jan 22;16(1):e1002726
pubmed: 30668565
Emerg Infect Dis. 2018 Nov;24(11):2119-2121
pubmed: 30334729
Lancet Infect Dis. 2019 Apr;19(4):439-446
pubmed: 30826189
PLoS Negl Trop Dis. 2016 Dec 7;10(12):e0005173
pubmed: 27926933
Bull World Health Organ. 2018 Jun 01;96(6):402-413D
pubmed: 29904223
Elife. 2018 Aug 14;7:
pubmed: 30103854
Science. 2016 Jul 22;353(6297):353-4
pubmed: 27417493
J Infect Dis. 2018 Jul 13;218(4):536-545
pubmed: 29618091
PLoS Negl Trop Dis. 2017 Jul 20;11(7):e0005786
pubmed: 28727726
PLoS Negl Trop Dis. 2016 May 17;10(5):e0004726
pubmed: 27186984
N Engl J Med. 2009 Jun 11;360(24):2536-43
pubmed: 19516034
Elife. 2020 Jan 28;9:
pubmed: 31987069
BMC Med. 2018 Oct 3;16(1):180
pubmed: 30285863
Int J Infect Dis. 2016 Apr;45:95-7
pubmed: 26923081
Science. 2019 Feb 8;363(6427):607-610
pubmed: 30733412
Elife. 2017 Sep 09;6:
pubmed: 28887877
PLoS Negl Trop Dis. 2016 Mar 17;10(3):e0004551
pubmed: 26986468
Emerg Infect Dis. 2014 Jun;20(6):1034-6
pubmed: 24856252
Elife. 2016 Nov 29;5:
pubmed: 27897973
mBio. 2017 Nov 14;8(6):
pubmed: 29138300
Cell. 2016 Aug 11;166(4):1016-1027
pubmed: 27475895
PLoS Negl Trop Dis. 2017 Apr 27;11(4):e0005568
pubmed: 28448507

Auteurs

Alasdair D Henderson (AD)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. alasdair.henderson1@lshtm.ac.uk.

Mike Kama (M)

Fiji Center for Diseases Control, Suva, Fiji.

Maite Aubry (M)

Institut Louis Malardé, Papeete, Tahiti, French Polynesia.

Stephane Hue (S)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Anita Teissier (A)

Institut Louis Malardé, Papeete, Tahiti, French Polynesia.

Taina Naivalu (T)

Fiji National University, Suva, Fiji.

Vinaisi D Bechu (VD)

Fiji Center for Diseases Control, Suva, Fiji.

Jimaima Kailawadoko (J)

Fiji Center for Diseases Control, Suva, Fiji.

Isireli Rabukawaqa (I)

Fiji Center for Diseases Control, Suva, Fiji.

Aalisha Sahukhan (A)

Fiji Center for Diseases Control, Suva, Fiji.

Martin L Hibberd (ML)

Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK.

Eric J Nilles (EJ)

Harvard Humanitarian Initiative, Cambridge, MA, USA.

Sebastian Funk (S)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Jimmy Whitworth (J)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Conall H Watson (CH)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Epidemic Diseases Research Group Oxford, University of Oxford, Oxford, UK.

Colleen L Lau (CL)

Research School of Population Health, The Australian National University, Canberra, ACT, Australia.

W John Edmunds (WJ)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Van-Mai Cao-Lormeau (VM)

Institut Louis Malardé, Papeete, Tahiti, French Polynesia.

Adam J Kucharski (AJ)

Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH